Efficacy of long acting once weekly dulaglutide compared with short acting twice-daily (bid) exenatide in patients with Type 2 diabetes mellitus (T2DM): a post-hoc analysis to det…

Aim: To investigate the response to long- and short-acting glucagon-like peptide-1 receptor agonists based on baseline HbA1c levels. The AWARD-1 trial compared once weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg to placebo and exenatide 10 µg bid in patients with T2DM on metformin and pioglitazone. Methods: The changes from baseline in HbA1c and percentages of patients reaching HbA1c targets (< 7.0%, ≤6.5%) with dulaglutide 1.5 mg and dulaglutide 0.75 mg at 26 weeks were analysed by baseline HbA1c (< 8.5%, ≥8.5%) and compared with placebo and exenatide. Results are presented (LS mean [SE]) for the change from…